Recent Advances in Drug Development for Hair Loss

Nanostructured lipid carriers can improve alopecia treatment by enhancing drug delivery and promoting hair growth.

In this study, the researchers evaluated the exposure-response relationship of ritlecitinib on eyebrow and eyelash regrowth and concluded that the established models justify selecting a 50 mg dose for patients with severe alopecia areata, while highlighting differing efficacy among evaluation methods.

This study observed that CXCL12 is highly co-expressed with androgen receptors in human hair follicle cells, and its inhibition via antibodies increased hair length, suggesting a potential treatment strategy for androgenic alopecia.

This study found that dupilumab's effects on alopecia areata varied depending on patients' immune profiles, with Th2-skewed females seeing improvements and Th1-driven males experiencing worsening.

In this review, researchers found that while exosomes show potential for treating hair loss with rare side effects reported among 125 patients, larger clinical trials with consistent manufacturing standards and regulatory oversight are needed to confirm efficacy and ensure safety.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

This review discusses the current state of alopecia areata treatments, noting that while recent advances such as Janus Kinase inhibitors show promise, persistent challenges like limited efficacy, safety concerns, and patient compliance highlight the need for innovative drug discovery and development strategies.

The study investigated immune cell patterns around the hair follicle infundibulum in androgenetic alopecia, revealing significant differences in immune signatures between patients with AGA and control donors, specifically noting an enrichment of CD4 cells in the patient group.

This review discusses the potential of therapeutic antibodies as an alternative treatment for androgenetic alopecia, highlighting the initial development stages and the need for further validation and optimization of targets like the prolactin receptor and Interleukin-6 receptor.

In this systematic review and meta-analysis, PRP therapy significantly improved hair density and thickness for women experiencing hair loss, with mild and transient adverse effects, suggesting potential tailored treatment protocols based on dosage, injection duration, and ethnicity.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

This review summarizes recent advancements in using exosomes for promoting hair growth, finding that exosomes from various cells, like dermal papilla and mesenchymal stem cells, show promise as a potential new treatment route for alopecia.

Finasteride can cause depression, suicidal thoughts, and lasting psychiatric and sexual issues.

IVL3001 is safe, effective, and better than oral finasteride for treating hair loss.

This study found that three-layer dissolving microneedles for delivering Minoxidil showed improved skin drug penetration and reduced irritation risk compared to traditional Minoxidil cream, suggesting a promising alternative for alopecia areata treatment.

This review discusses the potential role of thyroid receptor β agonists in treating androgenetic alopecia, reporting no new clinical results while highlighting their mechanism and anti-alopecia efficacy.

This study found that a microneedle system delivering VEGF and Ritlecitinib improved hair regeneration in mice with androgenetic alopecia, showing faster anagen onset and better hair quality compared to minoxidil.

This systematic review concluded that dutasteride was more effective than finasteride in increasing hair count for treating androgenetic alopecia in both males and females, with comparable side effects.

In this randomized clinical trial, oral minoxidil was not superior to topical minoxidil in increasing hair density in men with androgenetic alopecia over 24 weeks, though photographic analysis suggested oral minoxidil may work better on the vertex area of the scalp.

This review discusses the applications and potential of microneedles loaded with extracellular vesicles for tissue regenerative repair and disease diagnosis, but does not report new experimental findings.

This study observed that dupilumab may promote hair regrowth in alopecia areata patients, achieving significant results in a majority of cases without reported adverse events.

This study found that subcutaneous injection of a CXCL12 neutralizing antibody significantly promoted hair growth in androgenic alopecia and inhibited hair loss in alopecia areata in mouse models, suggesting its potential as a promising treatment for hair loss.

This review provides an overview of clinically approved small molecule drugs targeting androgen receptors and discusses therapeutic applications, without presenting new experimental results.

This study found that adipose-derived stem cells with DKK1 knocked out using CRISPR/Cas9 promoted hair growth in an alopecia areata model more effectively than untreated stem cells, suggesting DKK1 is a potential therapeutic target for this condition.

This study found that ITGA6-positive dermal sheath cup cells, identified by their superior migratory activity, may enhance cell-based therapy for male and female pattern hair loss by promoting cell migration into hair follicles.

This review of SVF treatment for androgenetic alopecia found a significant increase in hair density across studies with no serious adverse events, but calls for standardized protocols and further research.

In this study, injecting dermal sheath cup cells into affected areas of pattern hair loss improved hair thickness and patient-reported hair appearance in 62.9% of the participants, with better results in women, without serious side effects.

In this study on male androgenetic alopecia, the researchers reported significant increases in hair count, density, and thickness with minimal side effects over 6 weeks using adipose-derived stem cell conditioned media and minoxidil, but found no significant differences between concentrated and non-concentrated treatments.

This systematic review suggests that botulinum toxin may be effective for treating certain scalp conditions, but the current evidence varies widely in quality and often derives from small observational studies.

This study found that in mice, LSD1 interacting with HSP90 accelerates skin wound healing by enhancing HFSC glycolytic metabolism, proliferation, and differentiation via the c-MYC/LDHA axis.

This study found that a single intradermal injection of human dermal papilla cells increased hair follicle number and thickness in pigs, suggesting potential effectiveness for hair growth in humans.

This study concluded that both oral and topical spironolactone effectively treat androgenetic alopecia, with topical administration being safer and suitable for any gender, especially when combined with minoxidil.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This study found that platelet-rich plasma microneedles promoted hair regrowth in mice by facilitating angiogenesis and cell proliferation, showing promise for a minimally invasive hair regeneration treatment.

This study reported significant improvements in hair density, diameter, and patient satisfaction after using non-enzymatic stromal vascular fraction treatment for androgenic alopecia over six months.

This study found that intradermal injection of a cell-penetrating, AR-targeting asiRNA promoted hair growth and reduced androgen receptor expression in mouse models of androgenetic alopecia, suggesting its therapeutic potential.

This study reviewed recent developments in cell therapy for hair loss, finding adipose-derived stem cells and dermal sheath cup cells as promising alternatives to conventional treatments, albeit with varying effectiveness and challenges in trichogenecity and hair growth outcomes.

This review discusses the current understanding of frontal fibrosing alopecia's pathogenesis, highlighting genetic susceptibility, immune response involvement, and possible links to steroid hormones, but reports no new clinical results.

This study found that CXCL12 inhibits hair growth via the CXCR4/STAT signaling pathway, suggesting that targeting this pathway could be a promising approach for promoting hair growth.

This review examines the definition, classification, mechanism, clinical efficacy for hair regrowth, and potential adverse effects of platelet rich plasma, but does not present new experimental results.

In this study, researchers found that the thyroxine receptor agonist TDM10842 accelerated the onset of anagen, a hair growth phase, in C3H mice, potentially through activation of the Wnt/beta-catenin and Hedgehog pathways, with Pclaf playing a key role in this process.

This study found that for treating androgenetic alopecia, LC hair essence serum injections provided excellent results with fewer side effects compared to botulinum toxin A, which also showed significant efficacy but with higher associated costs and more frequent side effects.

This study found that combining basic fibroblast growth factor with minoxidil improved hair treatment efficiency and patient satisfaction compared to minoxidil alone for early-stage androgenetic alopecia in men.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

In this triple-blind randomized clinical trial, researchers found that oral minoxidil 0.25 mg tablets were as effective as 2% topical minoxidil for increasing hair diameter and density in women with female pattern hair loss, with similarly minor side effects.

This systematic review of five studies found that intradermal and intramuscular botulinum toxin injections showed promising hair growth outcomes for men with androgenic alopecia, but emphasizes caution due to a lack of control groups and small sample sizes.

This study reports that a single transplantation of autologous stromal vascular fraction significantly increased hair density and keratin score in androgenic alopecia patients within six months.

This study found that TGF-β2 may enhance collagen expression and spheroid formation in human dermal papilla cells, which could improve their hair inductivity and maintenance.

This study describes the development of microneedle array patches for finasteride that released the drug over 7 to 14 days in vitro, suggesting a potential alternative to oral treatments for long-term management of benign prostatic hyperplasia and androgenic alopecia.

This study found that while both cetirizine 1% and minoxidil 5% increased hair density in men with androgenetic alopecia, minoxidil showed a significantly higher improvement, and both treatments lost effectiveness after 8 weeks without use; cetirizine was well-tolerated with no significant adverse reactions.

In this study, selective inhibition of JAK3 signaling effectively prevented and reversed alopecia areata in a mouse model, while JAK2 inhibitors did not restore hair growth.

This study found that KY19382 can effectively promote hair regeneration and follicle neogenesis in mice and human hair models by activating Wnt/β-catenin signalling, suggesting potential use for alopecia treatment.

In this study, Nec-1s was found to promote hair growth and may target necroptosis and the Wnt/β-catenin pathway for potential treatment of hair loss.

This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.

In this study, human ADSC-CM treatment following nonablative fractional laser significantly increased hair density and volume in patients with androgenetic alopecia without any reported adverse effects.

This review discusses the role of Wnt/β-catenin signaling in hair follicle regeneration and highlights recent progress in developing hair loss treatments targeting this pathway, but reports no new clinical results.

This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.

In this randomized clinical trial, the authors reported that adipose-derived stem cell constituent extract topical solution increased hair density and thickness in patients with androgenetic alopecia over 16 weeks compared to placebo.

This article discusses the autoimmune causes of alopecia areata and reports no new clinical results.

In this study, intradermal injection of botulinum toxin was associated with increased hair growth in men with androgenetic alopecia through the suppression of TGF-β1 secretion from dermal papilla cells.

Finasteride and minoxidil together safely and effectively increase hair growth and density for androgenetic alopecia.

This study found that injecting autologous dermal sheath cup cells significantly increased hair density and diameter in male and female pattern hair loss compared to a placebo for up to 9 months.

This study found that oral dutasteride increased hair count more than intralesional administration in androgenetic alopecia, but more research is needed for a reliable comparison.

This study found that micrografts containing human hair follicle mesenchymal stem cells significantly increased hair count and density compared to placebo over 58 weeks in patients experiencing hair loss.

This review discusses adverse effects of 5 alpha-reductase inhibitors, particularly persistent side effects such as post-finasteride syndrome, and highlights the need for further investigation.

This study found that preconditioning adipose-derived stem cells with HB-EGF enhanced their ability to promote hair growth in vivo by increasing their motility, paracrine effects, and survival.

In this study, researchers developed a new self-administered finasteride delivery system using powder-carrying microneedles that improved hair growth efficacy and addressed safety concerns compared to topical finasteride gel by allowing sustained intradermal release of the drug for three days with a single application.

This study found that combining stromal vascular fraction with PRP injections significantly improved hair density and reduced hair loss more effectively than PRP alone in patients with androgenetic alopecia.

This review discusses emerging targets for developing drugs to treat hair loss and reports no new clinical results; the authors emphasize the potential for therapies that regenerate hair follicles.

This review discusses the advancements in intraoperative stem cell therapies and highlights their potential to improve hair regrowth, but it reports no new clinical results.

In a mouse model, this study demonstrated that a microneedle patch system using keratin and integrated with MSC-derived exosomes and UK5099 promoted hair regrowth more efficiently than traditional delivery methods.

Low oxygen levels can make hair-growing cells better at growing hair through a process involving reactive oxygen species.

In this study, patients receiving adipose-derived stromal vascular cell transplantation for alopecia areata experienced significant hair regeneration, increased growth, and improved hair quality after 3 and 6 months, indicating potential efficacy of this stem cell-based therapy for hair loss.

This review discusses advances in molecular biology and genetics related to androgenetic alopecia and reports no new clinical results.

This study found that glycolytic metabolism and lactate production are crucial for hair follicle stem cell activation, and manipulating these processes can stimulate the hair cycle.

This study reported that using human follicle stem cells isolated from hair bulge areas increased hair density by about 29% over baseline in patients with androgenetic alopecia, with significant improvements observed 23 weeks after the last treatment.

This review summarizes recent research on alopecia areata, highlighting advances in targeted therapies due to improved understanding of its immunopathogenesis, though it reports no new clinical results.

This study found that platelet-derived growth factor signaling is crucial for maintaining the hair follicle dermal stem cell pool and supporting their regenerative capacity.

This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.

In this pilot study, botulinum toxin was found to be a safe and effective treatment for androgenetic alopecia in most participants, though larger studies are needed to confirm these findings.

This study observed that applying JAK-STAT pathway inhibitors to mouse and human skin led to rapid hair growth by inducing the anagen phase of hair follicles.

This study identified a distinct cytokine activation signature in alopecia areata, involving TH2, TH1, IL-23, and IL-9/TH9 pathways, suggesting potential targeting strategies similar to those in psoriasis and atopic dermatitis.

This review discusses current knowledge on the biological mechanisms of different types of alopecia but reports no new clinical findings; the authors highlight future research directions, especially regarding epidermal stem cells and immune pathways.

This review discusses the potential applications of prostaglandin F2α analogs for certain types of alopecia and hypopigmentation, but reports no new experimental results.

Apremilast may help treat hair loss in alopecia areata.

This study found that PDGF-D acts as a potent mitogenic factor in adipose-derived stem cells, enhancing their proliferation, migration, and growth factor expression, suggesting its use as a preconditioning agent for ASC transplantation.

This study demonstrated that thyroid hormone receptors play a crucial role in hair growth and skin health, as mice lacking these receptors showed impaired hair cycling and wound healing.

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

This study concluded that the new subfractionation culturing method generates highly homogeneous adipose-derived stem cells with enhanced mitogenic, paracrine, and hair growth-promoting effects compared to traditional isolation methods.

This study found that vitamin C increased the survival, proliferation, and hair-regenerative potential of adipose-derived stem cells through the MAPK pathway and enhanced hair growth in mice.

This review assessed available treatments for female pattern hair loss and found that minoxidil improved hair regrowth compared to placebo, though high-quality evidence was limited for other interventions.

This article discusses the potential of using human hair follicles as a model to study prolactin's regulation and activities but reports no new experimental findings; the authors suggest further research in this area.

This review discusses the role of stem cells in alopecia pathogenesis, highlighting the differences between scarring and nonscarring types, and reports no new clinical results.

PGD2 stops hair growth and is higher in bald men with AGA.

In this study, IGF-I was shown to enhance human hair follicle growth, maintain the anagen phase, and increase expression of certain growth factors and anti-apoptotic markers.

This review discusses spironolactone's dermatologic applications, particularly for conditions like hirsutism and female pattern hair loss, but reports no new results; it also highlights safety concerns in pregnancy and men.

This review discusses techniques and models for assessing hair growth activity but reports no new clinical findings, emphasizing the need for standardization and improved animal models.

This study found that topical minoxidil modestly extended the anagen phase in mice by activating β-catenin activity in dermal papilla cells.

This review discusses the pathogenesis and challenges in treating primary cicatricial alopecia, highlighting the need to understand immune protection collapse in hair follicle stem cells; it reports no new clinical results.

This case report highlights a woman who developed new-onset alopecia areata after starting adalimumab for psoriatic arthritis, challenging the assumed role of TNF-alpha in the condition's pathogenesis.

This study found that human hair follicles express ATP-sensitive potassium channels, suggesting that minoxidil acts on these channels and that drugs targeting them may treat hair disorders.

This study found that the proteins GDNF, NTN, GFRα-1, GFRα-2, and c-Ret are differentially expressed during various stages of the human hair follicle cycle, with potential implications for hair biology.

This study found that prolactin plays a direct role in regulating the timing of hair growth cycles in mice by affecting the skin, rather than through other endocrine factors.

The study found that prolactin expressed in human scalp hair follicles acts as an autocrine modulator, inhibiting hair growth and promoting hair follicle regression, which may contribute to hair loss in hyper-prolactinemia patients.

This article reports a case where the IOP-lowering drug bimatoprost was associated with eyelash hypertrichosis.

This study found that minoxidil topical solution was associated with a dose-related occurrence of hypertrichosis, especially facial hair, in women treated for androgenetic alopecia.

This study found that VEGF significantly enhances perifollicular vascularization during the hair growth phase, accelerating hair regrowth and increasing follicle and hair size, while its inhibition retards hair growth.

This study found that minoxidil significantly increases VEGF mRNA and protein expression in dermal papilla cells, suggesting a role in enhancing hair follicle vascularization in androgenetic alopecia.

This study found that recombinant keratinocyte growth factor (rKGF) stimulated hair growth and provided a protective effect against alopecia in murine models, suggesting its role in hair follicle development and regeneration.